English

Atea Pharmaceuticals, Inc.

EDGAR

AVIR Quarterly report (10-Q) · filed 2026-08-12

29 filing records in this dataset, filed from 2020-10-09 to 2026-08-12. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

192 million USD

2021 Q4 · USD

Exact inputs and evidence

Revenue: 351367000 USD Source
Revenue: 159187000 USD Source

Operating margin

63.06%

2021 Q4 · %

Exact inputs and evidence

Operating Income: 138377000 USD Source
Operating Income: 17196000 USD Source
Revenue: 351367000 USD Source
Revenue: 159187000 USD Source

Operating cash flow

-75.4 million USD

2021 Q4 · USD

Exact inputs and evidence

Operating Cash Flow: -87005000 USD Source
Operating Cash Flow: -11582000 USD Source

Cash and cash equivalents: 76.5 million USD 2026-06-30 Source
Exact value

76548000 USD
Long-term debt including current maturities: Not available
Shares outstanding: 80.2 million shares 2026-06-30 Source
Exact value

80204699 shares

Reported share-count change

-1.15% · -933 thousand shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

81137478 shares · 2025-06-30· Source
80204699 shares · 2026-06-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

351 million USD

2021-01-01 – 2021-12-31

Exact inputs and evidence

Revenue: 65985000 USD · 2021-01-01 – 2021-03-31 Source
Revenue: 60391000 USD · 2021-04-01 – 2021-06-30 Source
Revenue: 32811000 USD · 2021-07-01 – 2021-09-30 Source
Revenue: 351367000 USD · 2021-01-01 – 2021-12-31 Source
Revenue: 159187000 USD · 2021-01-01 – 2021-09-30 Source

Net income

-165 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Net income: -42049000 USD · 2025-07-01 – 2025-09-30 Source
Net income: -158349000 USD · 2025-01-01 – 2025-12-31 Source
Net income: -113482000 USD · 2025-01-01 – 2025-09-30 Source
Net income: -45440000 USD · 2026-01-01 – 2026-03-31 Source
Net income: -32933000 USD · 2026-04-01 – 2026-06-30 Source

Operating cash flow

-152 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -103808000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -63433000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -132031000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -103808000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -46391000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -83475000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -46391000 USD · 2026-01-01 – 2026-03-31 Source

Capital expenditure

1.94 million USD

2022-01-01 – 2022-12-31

Exact inputs and evidence

Capital expenditure: 44000 USD · 2022-01-01 – 2022-03-31 Source
Capital expenditure: 1923000 USD · 2022-01-01 – 2022-06-30 Source
Capital expenditure: 44000 USD · 2022-01-01 – 2022-03-31 Source
Capital expenditure: 1943000 USD · 2022-01-01 – 2022-09-30 Source
Capital expenditure: 1923000 USD · 2022-01-01 – 2022-06-30 Source
Capital expenditure: 1943000 USD · 2022-01-01 – 2022-12-31 Source
Capital expenditure: 1943000 USD · 2022-01-01 – 2022-09-30 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-08-12.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 2 of 11 periods available· newest 2021-12-31
Operating income: 8 of 11 periods available· newest 2025-12-31
Net income: 8 of 11 periods available· newest 2025-12-31
Operating cash flow: 8 of 11 periods available· newest 2025-12-31
Capital expenditure: 5 of 11 periods available· newest 2022-12-31
Total assets: 7 of 11 periods available· newest 2025-12-31
Total liabilities: 7 of 11 periods available· newest 2025-12-31
Current assets: 7 of 11 periods available· newest 2025-12-31
Current liabilities: 7 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 8 of 11 periods available· newest 2025-12-31
long term debt: No compatible figures in this window
Shares outstanding: 7 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Net income
+USD 10.04 million

Prior period

−USD 168.39 million

2024-01-01 – 2024-12-31
Current period

−USD 158.35 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-158349000 − -168385000 = 10036000 USD

-168385000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-158349000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Atea Pharmaceuticals, Inc. · 2025-12-31 Atea Pharmaceuticals, Inc. (edgar:1593899) Year-over-year change in Net income: 10036000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1593899?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -158349000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1593899/000119312526094159/avir-20251231.htm#3387600 Filing: 000119312526094159 Input fundies:NetIncome: -168385000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1593899/000119312526094159/avir-20251231.htm#3389447 Filing: 000119312526094159
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 3.47 million

Prior period

−USD 135.5 million

2024-01-01 – 2024-12-31
Current period

−USD 132.03 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-132031000 − -135499000 = 3468000 USD

-135499000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-132031000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Atea Pharmaceuticals, Inc. · 2025-12-31 Atea Pharmaceuticals, Inc. (edgar:1593899) Year-over-year change in Operating cash flow: 3468000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1593899?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -132031000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1593899/000119312526094159/avir-20251231.htm#2359904 Filing: 000119312526094159 Input fundies:OperatingCashFlow: -135499000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1593899/000119312526094159/avir-20251231.htm#2361882 Filing: 000119312526094159
The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Revenue, Capital expenditure.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2021 2021-01-01 – 2021-12-31

Revenue USD 351.37 million 100% of revenue
Operating costs Derived USD 212.99 million 61% of revenue
Operating income USD 138.38 million 39% of revenue
Tax, interest and other Derived USD 17.19 million 4.9% of revenue
Net income USD 121.19 million 34% of revenue

Cash

Operating cash flow −USD 87.01 million −25% of revenue
Capital expenditure USD 4,000 0% of revenue
Free cash flow Derived −USD 87.01 million −25% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2020 Operating loss: operating costs were 123% of revenue.
2021 34%61%

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2020 2020-01-01 – 2020-12-31	48633000	59663000 Derived	-11030000	-83000 Derived	-10947000	296708000 Derived	Source 2020-01-01 – 2020-12-31: 48633000 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -11030000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -10947000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: 296734000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 26000 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	351367000	212990000 Derived	138377000	17187000 Derived	121190000	-87009000 Derived	Source 2021-01-01 – 2021-12-31: 351367000 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: 138377000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: 121190000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -87005000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 4000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 351.4M 2021

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20202020-12-31	Revenue	48633000	Revenue: 48633000 Open source
20212021-12-31	Revenue	351367000	Revenue: 351367000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

622.5% 2021

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Year over year	No prior comparable period	Revenue: 48633000 Open source
20212021-12-31	Year over year	622.5%	Revenue: 351367000 Open source Revenue: 48633000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin 39.4% 2021

Net margin 34.5% 2021

Free cash flow margin -24.8% 2021

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Operating margin	-22.7%	Operating Income: -11030000 Open source Revenue: 48633000 Open source
20212021-12-31	Operating margin	39.4%	Operating Income: 138377000 Open source Revenue: 351367000 Open source
20202020-12-31	Net margin	-22.5%	Net Income: -10947000 Open source Revenue: 48633000 Open source
20212021-12-31	Net margin	34.5%	Net Income: 121190000 Open source Revenue: 351367000 Open source
20202020-12-31	Free cash flow margin	610.1%	Revenue: 48633000 Open source Operating Cash Flow: 296734000 Open source Capital Expenditure: 26000 Open source
20212021-12-31	Free cash flow margin	-24.8%	Revenue: 351367000 Open source Operating Cash Flow: -87005000 Open source Capital Expenditure: 4000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -87M 2021

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20202020-12-31	Operating cash flow	296734000	Operating Cash Flow: 296734000 Open source
20212021-12-31	Operating cash flow	-87005000	Operating Cash Flow: -87005000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -87M 2021

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20202020-12-31	Free cash flow	296708000	Operating Cash Flow: 296734000 Open source Capital Expenditure: 26000 Open source
20212021-12-31	Free cash flow	-87009000	Operating Cash Flow: -87005000 Open source Capital Expenditure: 4000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

8.1% 2021

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Liabilities / assets	36.6%	Total Liabilities: 315831000 Open source Total Assets: 863632000 Open source
20212021-12-31	Liabilities / assets	8.1%	Total Liabilities: 62815000 Open source Total Assets: 772892000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

13.58× 2021

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Current assets / current liabilities	2.73×	Current Assets: 863477000 Open source Current Liabilities: 315795000 Open source
20212021-12-31	Current assets / current liabilities	13.58×	Current Assets: 772403000 Open source Current Liabilities: 56883000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2018 2018-01-01 – 2018-12-31	−USD 9.06 million Exact value Exact value: -9064000 USD 2018-01-01 – 2018-12-31: -9064000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Atea Pharmaceuticals, Inc. · 2018-12-31 Atea Pharmaceuticals, Inc. (edgar:1593899) Net Income: -9064000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1593899/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -9064000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1593899/000156459021016724/avir-20201231.xml#99842 Filing: 000156459021016724 The citation records this snapshot. The page link may show a newer release later.	−USD 7.91 million Exact value Exact value: -7908000 USD 2018-01-01 – 2018-12-31: -7908000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Atea Pharmaceuticals, Inc. · 2018-12-31 Atea Pharmaceuticals, Inc. (edgar:1593899) Operating Cash Flow: -7908000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1593899/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -7908000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1593899/000156459021016724/avir-20201231.xml#121510 Filing: 000156459021016724 The citation records this snapshot. The page link may show a newer release later.	USD 12,000 Exact value Exact value: 12000 USD 2018-01-01 – 2018-12-31: 12000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Atea Pharmaceuticals, Inc. · 2018-12-31 Atea Pharmaceuticals, Inc. (edgar:1593899) Capital Expenditure: 12000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1593899/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 12000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1593899/000156459021016724/avir-20201231.xml#122136 Filing: 000156459021016724 The citation records this snapshot. The page link may show a newer release later.	−USD 7.92 million Calculation and evidence -7908000 − 12000 USD Exact free cash flow: -7920000 USD 2018-01-01 – 2018-12-31: -7908000 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 12000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Atea Pharmaceuticals, Inc. · 2018-12-31 Atea Pharmaceuticals, Inc. (edgar:1593899) Free cash flow: -7920000 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1593899?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -7908000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1593899/000156459021016724/avir-20201231.xml#121510 Filing: 000156459021016724 Input fundies:CapitalExpenditure: 12000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1593899/000156459021016724/avir-20201231.xml#122136 Filing: 000156459021016724 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	−USD 14.03 million Exact value Exact value: -14034000 USD 2019-01-01 – 2019-12-31: -14034000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Atea Pharmaceuticals, Inc. · 2019-12-31 Atea Pharmaceuticals, Inc. (edgar:1593899) Net Income: -14034000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1593899/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -14034000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1593899/000156459022007672/avir-10k_20211231.htm#3275598 Filing: 000156459022007672 The citation records this snapshot. The page link may show a newer release later.	−USD 12.83 million Exact value Exact value: -12829000 USD 2019-01-01 – 2019-12-31: -12829000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Atea Pharmaceuticals, Inc. · 2019-12-31 Atea Pharmaceuticals, Inc. (edgar:1593899) Operating Cash Flow: -12829000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1593899/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -12829000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1593899/000156459022007672/avir-10k_20211231.htm#2539583 Filing: 000156459022007672 The citation records this snapshot. The page link may show a newer release later.	USD 2,000 Exact value Exact value: 2000 USD 2019-01-01 – 2019-12-31: 2000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Atea Pharmaceuticals, Inc. · 2019-12-31 Atea Pharmaceuticals, Inc. (edgar:1593899) Capital Expenditure: 2000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1593899/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1593899/000156459022007672/avir-10k_20211231.htm#2550917 Filing: 000156459022007672 The citation records this snapshot. The page link may show a newer release later.	−USD 12.83 million Calculation and evidence -12829000 − 2000 USD Exact free cash flow: -12831000 USD 2019-01-01 – 2019-12-31: -12829000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 2000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Atea Pharmaceuticals, Inc. · 2019-12-31 Atea Pharmaceuticals, Inc. (edgar:1593899) Free cash flow: -12831000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1593899?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -12829000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1593899/000156459022007672/avir-10k_20211231.htm#2539583 Filing: 000156459022007672 Input fundies:CapitalExpenditure: 2000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1593899/000156459022007672/avir-10k_20211231.htm#2550917 Filing: 000156459022007672 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 10.95 million Exact value Exact value: -10947000 USD 2020-01-01 – 2020-12-31: -10947000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Atea Pharmaceuticals, Inc. · 2020-12-31 Atea Pharmaceuticals, Inc. (edgar:1593899) Net Income: -10947000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1593899/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -10947000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1593899/000095017023005186/avir-20221231.htm#4247461 Filing: 000095017023005186 The citation records this snapshot. The page link may show a newer release later.	USD 296.73 million Exact value Exact value: 296734000 USD 2020-01-01 – 2020-12-31: 296734000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Atea Pharmaceuticals, Inc. · 2020-12-31 Atea Pharmaceuticals, Inc. (edgar:1593899) Operating Cash Flow: 296734000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1593899/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 296734000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1593899/000095017023005186/avir-20221231.htm#3103307 Filing: 000095017023005186 The citation records this snapshot. The page link may show a newer release later.	USD 26,000 Exact value Exact value: 26000 USD 2020-01-01 – 2020-12-31: 26000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Atea Pharmaceuticals, Inc. · 2020-12-31 Atea Pharmaceuticals, Inc. (edgar:1593899) Capital Expenditure: 26000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1593899/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 26000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1593899/000095017023005186/avir-20221231.htm#3114447 Filing: 000095017023005186 The citation records this snapshot. The page link may show a newer release later.	USD 296.71 million Calculation and evidence 296734000 − 26000 USD Exact free cash flow: 296708000 USD 2020-01-01 – 2020-12-31: 296734000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 26000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Atea Pharmaceuticals, Inc. · 2020-12-31 Atea Pharmaceuticals, Inc. (edgar:1593899) Free cash flow: 296708000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1593899?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 296734000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1593899/000095017023005186/avir-20221231.htm#3103307 Filing: 000095017023005186 Input fundies:CapitalExpenditure: 26000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1593899/000095017023005186/avir-20221231.htm#3114447 Filing: 000095017023005186 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	USD 121.19 million Exact value Exact value: 121190000 USD 2021-01-01 – 2021-12-31: 121190000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Atea Pharmaceuticals, Inc. · 2021-12-31 Atea Pharmaceuticals, Inc. (edgar:1593899) Net Income: 121190000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1593899/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: 121190000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1593899/000095017023005186/avir-20221231.htm#4244487 Filing: 000095017023005186 The citation records this snapshot. The page link may show a newer release later.	−USD 87.01 million Exact value Exact value: -87005000 USD 2021-01-01 – 2021-12-31: -87005000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Atea Pharmaceuticals, Inc. · 2021-12-31 Atea Pharmaceuticals, Inc. (edgar:1593899) Operating Cash Flow: -87005000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1593899/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -87005000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1593899/000095017023005186/avir-20221231.htm#3101169 Filing: 000095017023005186 The citation records this snapshot. The page link may show a newer release later.	USD 4,000 Exact value Exact value: 4000 USD 2021-01-01 – 2021-12-31: 4000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Atea Pharmaceuticals, Inc. · 2021-12-31 Atea Pharmaceuticals, Inc. (edgar:1593899) Capital Expenditure: 4000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1593899/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 4000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1593899/000095017023005186/avir-20221231.htm#3112288 Filing: 000095017023005186 The citation records this snapshot. The page link may show a newer release later.	−USD 87.01 million Calculation and evidence -87005000 − 4000 USD Exact free cash flow: -87009000 USD 2021-01-01 – 2021-12-31: -87005000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 4000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Atea Pharmaceuticals, Inc. · 2021-12-31 Atea Pharmaceuticals, Inc. (edgar:1593899) Free cash flow: -87009000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1593899?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -87005000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1593899/000095017023005186/avir-20221231.htm#3101169 Filing: 000095017023005186 Input fundies:CapitalExpenditure: 4000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1593899/000095017023005186/avir-20221231.htm#3112288 Filing: 000095017023005186 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 115.91 million Exact value Exact value: -115909000 USD 2022-01-01 – 2022-12-31: -115909000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Atea Pharmaceuticals, Inc. · 2022-12-31 Atea Pharmaceuticals, Inc. (edgar:1593899) Net Income: -115909000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1593899/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -115909000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1593899/000095017024022226/avir-20231231.htm#2849581 Filing: 000095017024022226 The citation records this snapshot. The page link may show a newer release later.	−USD 120.98 million Exact value Exact value: -120982000 USD 2022-01-01 – 2022-12-31: -120982000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Atea Pharmaceuticals, Inc. · 2022-12-31 Atea Pharmaceuticals, Inc. (edgar:1593899) Operating Cash Flow: -120982000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1593899/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -120982000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1593899/000095017024022226/avir-20231231.htm#2104354 Filing: 000095017024022226 The citation records this snapshot. The page link may show a newer release later.	USD 1.94 million Exact value Exact value: 1943000 USD 2022-01-01 – 2022-12-31: 1943000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Atea Pharmaceuticals, Inc. · 2022-12-31 Atea Pharmaceuticals, Inc. (edgar:1593899) Capital Expenditure: 1943000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1593899/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1943000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1593899/000095017024022226/avir-20231231.htm#2109168 Filing: 000095017024022226 The citation records this snapshot. The page link may show a newer release later.	−USD 122.93 million Calculation and evidence -120982000 − 1943000 USD Exact free cash flow: -122925000 USD 2022-01-01 – 2022-12-31: -120982000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 1943000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Atea Pharmaceuticals, Inc. · 2022-12-31 Atea Pharmaceuticals, Inc. (edgar:1593899) Free cash flow: -122925000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1593899?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -120982000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1593899/000095017024022226/avir-20231231.htm#2104354 Filing: 000095017024022226 Input fundies:CapitalExpenditure: 1943000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1593899/000095017024022226/avir-20231231.htm#2109168 Filing: 000095017024022226 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 135.96 million Exact value Exact value: -135956000 USD 2023-01-01 – 2023-12-31: -135956000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Atea Pharmaceuticals, Inc. · 2023-12-31 Atea Pharmaceuticals, Inc. (edgar:1593899) Net Income: -135956000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1593899/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -135956000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1593899/000095017025034808/avir-20241231.htm#3082832 Filing: 000095017025034808 The citation records this snapshot. The page link may show a newer release later.	−USD 85.4 million Exact value Exact value: -85395000 USD 2023-01-01 – 2023-12-31: -85395000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Atea Pharmaceuticals, Inc. · 2023-12-31 Atea Pharmaceuticals, Inc. (edgar:1593899) Operating Cash Flow: -85395000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1593899/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -85395000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1593899/000095017025034808/avir-20241231.htm#2221984 Filing: 000095017025034808 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2024 2024-01-01 – 2024-12-31	−USD 168.39 million Exact value Exact value: -168385000 USD 2024-01-01 – 2024-12-31: -168385000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Atea Pharmaceuticals, Inc. · 2024-12-31 Atea Pharmaceuticals, Inc. (edgar:1593899) Net Income: -168385000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1593899/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -168385000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1593899/000119312526094159/avir-20251231.htm#3389447 Filing: 000119312526094159 The citation records this snapshot. The page link may show a newer release later.	−USD 135.5 million Exact value Exact value: -135499000 USD 2024-01-01 – 2024-12-31: -135499000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Atea Pharmaceuticals, Inc. · 2024-12-31 Atea Pharmaceuticals, Inc. (edgar:1593899) Operating Cash Flow: -135499000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1593899/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -135499000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1593899/000119312526094159/avir-20251231.htm#2361882 Filing: 000119312526094159 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2025 2025-01-01 – 2025-12-31	−USD 158.35 million Exact value Exact value: -158349000 USD 2025-01-01 – 2025-12-31: -158349000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Atea Pharmaceuticals, Inc. · 2025-12-31 Atea Pharmaceuticals, Inc. (edgar:1593899) Net Income: -158349000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1593899/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -158349000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1593899/000119312526094159/avir-20251231.htm#3387600 Filing: 000119312526094159 The citation records this snapshot. The page link may show a newer release later.	−USD 132.03 million Exact value Exact value: -132031000 USD 2025-01-01 – 2025-12-31: -132031000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Atea Pharmaceuticals, Inc. · 2025-12-31 Atea Pharmaceuticals, Inc. (edgar:1593899) Operating Cash Flow: -132031000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1593899/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -132031000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1593899/000119312526094159/avir-20251231.htm#2359904 Filing: 000119312526094159 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

29 filings · 1,491 latest values · 1,491 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001593899, 1593899, AVIR, edgar:1593899

Also known as ATEA PHARMACEUTICALS, INC., Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals, Inc.

Latest quarter

Revenue

Operating margin

Operating cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Capital expenditure

Company performance

What changed year over year

Net income

Operating cash flow

Where revenue goes

2021 2021-01-01 – 2021-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation